

A POWERFUL PARTNERSHIP
FOR THE SCALABLE
GMP MANUFACTURE OF
CAP[®] BASED VIRAL VECTORS



Scalable Production of Viral Gene Therapy Vectors

In the rapidly growing field of gene therapy, the lack of scalable production systems remains a major hurdle in establishing gene transfer via viral vectors as an economically sustainable therapeutic option. CEVEC Pharmaceuticals GmbH and Paragon Bioservices combine their respective expertise in CEVEC's proprietary CAP-GT platform and Paragon's high-quality biopharmaceutical GMP production to provide an unprecedented solution for industrial scale manufacture of viral gene therapy vectors in North America.

CAP-GT features:

- Regulatory endorsed human high density suspension cells
- Platform for industrial scale AV, AAV and LV vector production
- Production in chemically defined serum free medium
- Absence of undesired replication competent particles during adenoviral vector production

CEVEC and its preferred CDMO partner for North America, Paragon Bioservices, have the following joint offering up to clinical phase 2:

- Development of stable producer cell lines
- Feasibility studies
- Generation of master and working cell banks
- Process development
- GMP manufacturing
- Aseptic Fill/Finish

For further information please contact:

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen-Str. 60-62 | 51105 Cologne | Germany
+49 (0)221 46020800 | info@cevec.com | www.cevec.com

Paragon Bioservices Inc.

Baltimore, MD | USA
+1 800 545 65 69 | +1 410 975 40 50 | www.paragonbioservices.com